Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wu, Che Hsiung ^a,b   Yang, Ya Wen ^c   Hung, Szu Chun ^a,b   Tsai, Yao Chou ^a   Hu, Ya Hui ^a   Lin, Yen Hung ^c   Chu, Tzong Shinn ^c   Wu, Kwan Dun ^c   Wu, Vin Cent ^c  

^a TAIPEI TZU CHI HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; AGED; BIOSYNTHESIS; BLOOD; BODY FLUID; CLINICAL TRIAL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; ODDS RATIO; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL ADENOMA; AGED; AGED, 80 AND OVER; ALDOSTERONE; BODY FLUIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; ODDS RATIO; RISK FACTORS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84945218857     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15297     Document Type: Article

References (40)

1. Young, W. F. Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 144, 2208-2213 (2003).
2. Nomura, K. et al. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab 75, 323-327 (1992).
3. Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45, 1243-1248 (2005).
4. Group, T. S. et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 54, 665-673 (2009).
5. Fardella, C. E., Mosso, L. M., Carvajal, C. A. [Primary aldosteronism]. Rev Med Chil 136, 905-914 (2008).
6. Ichikawa, S. et al. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism. Jpn Circ J 48, 1184-1196 (1984).
7. Agarwal, R., Andersen, M. J., Pratt, J. H. On the importance of pedal edema in hemodialysis patients. Clin J Am Soc Nephrol 3, 153-158 (2008).
8. Matthie, J. R. Bioimpedance measurements of human body composition: critical analysis and outlook. Expert Rev Med Devices 5, 239-261 (2008).
9. Jaffrin, M. Y., Morel, H. Body fluid volumes measurements by impedance: A review of bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods. Med Eng Phys 30, 1257-1269 (2008).
10. Moissl, U. M. et al. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas 27, 921-933 (2006).
11. Wabel, P., Chamney, P., Moissl, U., Jirka, T. Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif 27, 75-80 (2009).
12. Wu, K. D. et al. Preoperative diagnosis and localization of aldosterone-producing adenoma by adrenal venous sampling after administration of metoclopramide. J Formos Med Assoc 100, 598-603 (2001).
13. Chamney, P. W. et al. A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr 85, 80-89 (2007).
14. Wieskotten, S. et al. Bioimpedance-based identification of malnutrition using fuzzy logic. Physiol Meas 29, 639-654 (2008).
15. Zeger, S. L., Liang, K. Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42, 121-130 (1986).
16. Ma, Y., Mazumdar, M., Memtsoudis, S. G. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Reg Anesth Pain Med 37, 99-105 (2012).
17. Wu, V. C. et al. Effect of diuretic use on 30-day postdialysis mortality in critically ill patients receiving acute dialysis. PLoS One 7, e30836 (2012).
18. Catena, C. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168, 80-85 (2008).
19. Sechi, L. A., Colussi, G., Di Fabio, A., Catena, C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 23, 1253-1260 (2010).
20. Wu, V. C. et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 29, 1778-1786 (2011).
21. Strauch, B. et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 21, 1086-1092 (2008).
22. Mulatero, P. et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 93, 1366-1371 (2008).
23. Catena, C. et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911-918 (2007).
24. Reincke, M. et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 60, 618-624 (2012).
25. Catena, C. et al. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 42, 440-445 (2010).
26. Rossi, G. P. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62, 62-69 (2013).
27. Miyake, Y. et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J 61, 35-40 (2014).
28. Mulatero, P. et al. Long-term cardio-and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 98, 4826-4833 (2013).
29. Stehr, C. B. et al. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 28, 2120-2126 (2010).
30. Vogt, B., Burnier, M. Aldosterone and cardiovascular risk. Curr Hypertens Rep 11, 450-455 (2009).
31. Kapadia, S. R. et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 81, 187-195 (1997).
32. Vega, A., Quiroga, B., Abad, S., Ruiz, C., Lopez-Gomez, J. M. Study on overhydration in dialysis patients and its association with inflammation. Nefrologia 34, 579-583 (2014).
33. O'Lone, E. L., Visser, A., Finney, H., Fan, S. L. Clinical significance of multi-frequency bioimpedance spectroscopy in peritoneal dialysis patients: independent predictor of patient survival. Nephrol Dial Transplant 29, 1430-1437 (2014).
34. Feldman, A. M. et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35, 537-544 (2000).
35. Torre-Amione, G. et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27, 1201-1206 (1996).
36. Wu, V. C. et al. Kidney impairment in primary aldosteronism. Clin Chim Acta 412, 1319-1325 (2011).
37. Sechi, L. A. et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 295, 2638-2645 (2006).
38. Nishimura, M. et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 33, 261-266 (1999).
39. Reincke, M. et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 94, 869-875 (2009).
40. Danforth, D. N. Jr., Orlando, M. M., Bartter, F. C., Javadpour, N. Renal changes in primary aldosteronism. J Urol 117, 140-144 (1977).